Accéder au contenu
Merck

SPP1 promotes Schwann cell proliferation and survival through PKCα by binding with CD44 and αvβ3 after peripheral nerve injury.

Cell & bioscience (2020-08-28)
Jiang-Bo Wang, Zhan Zhang, Jian-Nan Li, Tuo Yang, Shuang Du, Rang-Juan Cao, Shu-Sen Cui
RÉSUMÉ

Schwann cells (SCs) play a crucial role in Wallerian degeneration after peripheral nerve injury. The expression of genes in SCs undergo a series of changes, which greatly affect the proliferation and apoptosis of SCs as well as the fate of peripheral nerve regeneration. However, how do these genes regulate the proliferation and apoptosis of SCs remains unclear. SPP1 and PKCα were found upregulated after human median peripheral nerve injury, which promoted SCs proliferation and survival. The promoted proliferation and inhibited apoptosis by SPP1 were blocked after the treatment of PKCα antagonist Gö6976. Whereas, the inhibited proliferation and enhanced apoptosis induced by silence of SPP1 could be rescued by the activation of PKCα, which suggested that SPP1 functioned through PKCα. Moreover, both CD44 and αvβ3 were found expressed in SCs and increased after peripheral nerve injury. Silence of CD44 or β3 alleviated the increased proliferation and inhibited apoptosis induced by recombinant osteopontin, suggesting the function of SPP1 on SCs were dependent on CD44 and β3. These results suggested that SPP1 promoted proliferation and inhibited apoptosis of SCs through PKCα signaling pathway by binding with CD44 and αvβ3. This study provides a potential therapeutic target for improving peripheral nerve recovery.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Phorbol 12-myristate 13-acétate, ≥99% (TLC), film or powder
Sigma-Aldrich
Cytosine β-D-arabinofuranoside, crystalline, ≥90% (HPLC)
Sigma-Aldrich
Monoclonal Anti-S-100 (β-Subunit) antibody produced in mouse, clone SH-B1, ascites fluid
Sigma-Aldrich
Monoclonal Anti-Thy 1.1 antibody produced in mouse, clone TN-26, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
MISSION® esiRNA, targeting human CD44